ReviewDrug design, development and therapy2026
Effect of Remimazolam on Postoperative Delirium in Elderly Surgical Patients: A Critical Review of Pharmacological Mechanisms and Clinical Evidence.
Review in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Postoperative delirium (POD) affects 4-53% of elderly surgical patients, and is linked to prolonged hospitalization, functional decline, and elevated mortality. Traditional benzodiazepines are confirmed POD risk factors due to accumulation of long-acting metabolites. Remimazolam, an ultra-short-acting benzodiazepine metabolized by tissue esterases, is a promising alternative. However, existing reviews pool heterogeneous surgical populations, and overlook procedure-specific pathophysiology as well as the confounding effect of flumazenil reversal on delirium assessment. Methods: We performed a focused literature search of PubMed/MEDLINE, Embase, and the Cochrane Library to June 2026, using terms including remimazolam, postoperative delirium, elderly, and surgery. Randomized controlled trials (RCTs), cohort studies, meta-analyses, and mechanistic studies were included, with reference lists hand-searched. Data were synthesized narratively, with emphasis on orthopedic surgery, frailty stratification, and mechanistic plausibility. Results: Recent RCTs in frail elderly surgery patients show remimazolam does not significantly raise POD incidence compared with propofol, consistent with pooled meta-analytic findings. Remimazolam reduces intraoperative hypotension and vasopressor requirements, which are independent POD risk factors. Its potential neuroprotective mechanisms include attenuated systemic inflammation, microglial M2 polarization, preserved cerebral perfusion, and maintained sleep architecture. Routine flumazenil reversal in multiple trials is a key methodological confounder that may mask early emergence delirium. Remimazolam retains class-related risks such as respiratory depression, with limited long-term ICU data and unproven cost-effectiveness. Conclusion: Remimazolam does not increase POD in elderly surgical patients versus propofol or dexmedetomidine, while offering better hemodynamic stability. It serves as a valuable option for frail patients with cardiovascular comorbidities undergoing high-risk orthopedic procedures. Future RCTs should standardize frailty assessment, apply flumazenil-free delirium screening windows, enroll cognitively vulnerable populations, and evaluate long-term cognitive and cost outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.